Dec 31, 2025 • The Globe and Mail
SOMEWHAT-BULLISH
How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?
Boston Scientific's Cardiovascular segment, operating in a $50 billion market, anticipates nearly 9% growth through its long-range plan, driven by strong performance in Electrophysiology and Interventional Cardiology Therapies. The company expects to outpace overall market growth, with key products like WATCHMAN serving as significant growth engines, bolstered by positive clinical trial outcomes. While also highlighting recent developments from peers Medtronic and Johnson & Johnson, the article notes Boston Scientific's stock performance and a "Buy" rating from Zacks.
Dec 31, 2025 • MarketBeat
SOMEWHAT-BULLISH
Lee Johnson Capital Management LLC Makes New $2.60 Million Investment in Medtronic PLC $MDT
Lee Johnson Capital Management LLC has made a new $2.60 million investment in Medtronic PLC (NYSE:MDT) during the third quarter, acquiring 27,303 shares. The medical technology company has seen strong institutional interest, with hedge funds increasing or initiating positions, and recently beat quarterly earnings expectations with $1.36 EPS and $8.96B revenue. Medtronic also declared a quarterly dividend of $0.71 per share and maintains a "Moderate Buy" consensus rating from analysts.
Dec 31, 2025 • MarketBeat
SOMEWHAT-BULLISH
Calamos Advisors LLC Has $51.24 Million Stock Holdings in Medtronic PLC $MDT
Calamos Advisors LLC significantly increased its stake in Medtronic PLC (NYSE:MDT) by 27.9% in Q3, now holding 538,018 shares valued at approximately $51.24 million. Medtronic recently exceeded Q1 earnings expectations and provided a positive FY2026 guidance, while analysts maintain a "Moderate Buy" rating with an average target price near $109.94. The company also declared a quarterly dividend of $0.71 per share, representing an annualized yield of about 2.9%.
Dec 31, 2025 • MarketBeat
NEUTRAL
Boston Trust Walden Corp Sells 85,690 Shares of Medtronic PLC $MDT
Boston Trust Walden Corp significantly reduced its stake in Medtronic PLC by selling 85,690 shares, decreasing their holdings by 62.2%. Despite this reduction, other institutional investors like Brighton Jones LLC and Focus Partners Advisor Solutions LLC increased their positions in Medtronic. The company maintains a "Moderate Buy" rating among analysts with a consensus target price of $109.94.
Dec 31, 2025 • openPR.com
SOMEWHAT-BULLISH
Disposable Insulin Pumps Market is expected to reach US$ 6.9 billion by 2032 | Major Companies - Medtronic, Roche, Animas Corporation, Tandem Diabetes Care.
The Global Disposable Insulin Pumps Market is projected to grow from US$ 3.83 billion in 2024 to US$ 6.9 billion by 2032, exhibiting a CAGR of 7.76%. This growth is driven by recent innovations and increasing adoption of tubeless patch pumps for diabetes management in regions like the US and Europe. Key players in this market include Medtronic, Insulet Corporation, and Roche.
Dec 30, 2025 • Insider Monkey
NEUTRAL
Bearish Options Activity Emerges on Medtronic plc (MDT) Despite Long-Term Growth Outlook
Medtronic (MDT) is experiencing bearish options activity, with significant put volume reported despite positive regulatory news and long-term growth prospects. This comes after Truist Securities lowered its price objective on MDT due to macro headwinds. The company recently filed to spin off its Diabetes business as MiniMed, aiming to focus on higher-growth segments.